About Cenexi
Cenexi is a company based in Fontenay-sous-bois (France) founded in 2004 by Philippe Mougin was acquired by Gland Pharma in November 2022. Cenexi offers products and services including Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services. Cenexi operates in a competitive market with competitors including Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
- Headquarter Fontenay-sous-bois, France
- Founders Philippe Mougin
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$492.01 K (USD), Grant
Sep 28, 2023
-
Investors
Gland Pharma
& 4 more
-
Employee Count
Not available
-
Acquired by
Gland Pharma
(Nov 29, 2022)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cenexi
Cenexi offers a comprehensive portfolio of products and services, including Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services.
Produces sterile products like ampoules and prefilled syringes for pharmaceuticals
Manufactures items such as tablets, capsules, and syrups for drug production
Offers expertise in pharmaceutical development and industrial transfer processes
Funding Insights of Cenexi
Investors in Cenexi
Cenexi has secured backing from 5 investors, including institutional and venture fund investors. Prominent investors backing the company include Gland Pharma, European Union and Ministry of Economy, Finance and Industrial and Digital Sovereignty.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Private investment firm specializing in markets and partnerships.
|
Locked | Locked | Locked | |
|
Financial investment management services are provided by Indigo Capital.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Cenexi
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cenexi
Investment portfolio details for Cenexi
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cenexi
Detailed financials for Cenexi
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cenexi Comparisons
Peer comparison for Cenexi
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cenexi
Cenexi operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Unither, Akums, Recipharm, Jubilant Life Sciences and CoreRx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Contract development and manufacturing organization for proprietary and generic drugs
|
|
| Locked | Locked | Locked |
CDMO focusing on spectrum of dosage forms and therapeutic segments
|
|
| Locked | Locked | Locked |
Pharmaceutical development and manufacturing services are offered contractually.
|
|
| Locked | Locked | Locked |
Company offering a suite of R&D and manufacturing services for small molecules and generics
|
|
| Locked | Locked | Locked |
CDMO with a focus on early phase drug product development
|
|
| Locked | Locked | Locked |
Biopharma regulatory affairs, quality control, and strategy services are provided.
|
Detailed competitors of Cenexi
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cenexi
Complete news archive for Cenexi
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cenexi
Cenexi was founded in 2004 and raised its 1st funding round 4 years after it was founded.
Cenexi is headquartered in Fontenay-sous-bois, France. It is registered at Fontenay-sous-bois, Val-de-marne, France.
Philippe Mougin is the current CEO of Cenexi. They have also founded this company.
Cenexi was founded in 2004 as a pharmaceutical contract development and manufacturing organization. Services encompass pre-formulation studies and formulation development across dosage forms such as sterile and solid variants. Facilities have been approved by regulatory bodies including FDA, EMEA, PMDA, and ANVISA, supporting operations in the global pharmaceutical sector.
Cenexi's top competitors include Jubilant Life Sciences, Akums and Nectar Lifesciences.
Cenexi offers Sterile Dosage Forms, Non-Sterile Dosage Forms, and Development Services.
Cenexi has 5 investors. Key investors include Gland Pharma, European Union, Ministry of Economy, Finance and Industrial and Digital Sovereignty, Ardian, and Indigo Capital.